Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [21] Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
    Toji, Yuta
    Takeuchi, Shintaro
    Ebihara, Yuma
    Kurashima, Yo
    Harada, Kazuaki
    Hayashi, Mariko
    Abe, Hirotake
    Wada, Hideyuki
    Yorinaga, Satoko
    Shichinohe, Toshiaki
    Tomaru, Utano
    Komatsu, Yoshito
    Hirano, Satoshi
    SURGICAL CASE REPORTS, 2024, 10 (01):
  • [22] Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
    Pizzuti, Laura
    Sergi, Domenico
    Sperduti, Isabella
    Di Lauro, Luigi
    Mazzotta, Marco
    Botti, Claudio
    Izzo, Fiorentino
    Marchetti, Luca
    Tomao, Silverio
    Marchetti, Paolo
    Natoli, Clara
    Grassadonia, Antonino
    Gamucci, Teresa
    Mentuccia, Lucia
    Magnolfi, Emanuela
    Vaccaro, Angela
    Cassano, Alessandra
    Rossi, Ernesto
    Botticelli, Andrea
    Sini, Valentina
    Sarobba, Maria G.
    Fabbri, Maria Agnese
    Moscetti, Luca
    Astone, Antonio
    Michelotti, Andrea
    De Angelis, Claudia
    Bertolini, Ilaria
    Angelini, Francesco
    Ciliberto, Gennaro
    Maugeri-Sacca, Marcello
    Giordano, Antonio
    Barba, Maddalena
    Vici, Patrizia
    CANCER BIOLOGY & THERAPY, 2018, 19 (04) : 328 - 334
  • [23] Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
    Shingaki, Sumito
    Kogawa, Takahiro
    Shimokawa, Mototsugu
    Haranol, Kenichi
    Naito, Yoichi
    Kusuharal, Shota
    Fujimoto, Yumi
    Matsubaral, Nobuaki
    Hosono, Ako
    Mukail, Hirofumi
    Onishi, Tatsuya
    Hojo, Takashi
    Mukohara, Toru
    JOURNAL OF CANCER, 2020, 11 (14): : 4099 - 4105
  • [24] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
    Shen, Lin
    Zhang, Yanqiao
    Li, Ziyu
    Zhang, Xiaotian
    Gao, Xiangyu
    Liu, Bo
    Wang, Yusheng
    Ba, Yi
    Li, Ning
    Zhang, Ruixing
    Zhang, Jingdong
    Chen, Ye
    Chen, Jian
    Huang, Mingzhu
    Fu, Yang
    Liu, Mulin
    Liu, Zheng
    Zhao, Jun
    Li, Wei
    Wei, Jia
    Li, Changzheng
    Xu, Nong
    Guo, Zengqing
    Cao, Bangwei
    Liu, Lian
    Nie, Peng
    Wan, Lixin
    Sheng, Lili
    Liu, Zhenyang
    He, Yifu
    Gu, Kangsheng
    Wu, Guowu
    Wang, Weibo
    Zhang, Futong
    Qiu, Wensheng
    Guo, Jun
    Ying, Jieer
    Pan, Hongming
    Xu, Huiting
    Yuan, Yuan
    Bai, Yuansong
    Wang, Zhenghua
    Xu, Jiye
    Zhao, Xuehong
    Liu, Hao
    Zhang, Xizhi
    Dai, Wenxiang
    Xu, Hongyan
    Liu, Ming
    Xie, Lin
    NATURE MEDICINE, 2025, : 1163 - 1170
  • [25] Maintenance durvalumab after fi rst-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
    Fong, C.
    Patel, B.
    Peckitt, C.
    Bourmpaki, E.
    Satchwell, L.
    Cromarty, S.
    Kidd, S.
    von Loga, K.
    Uhlik, M.
    Begum, R.
    Rana, T.
    Waddell, T.
    Darby, S.
    Bradshaw, A.
    Roques, T.
    Morgan, C.
    Rees, C.
    Herbertson, R.
    Das, P.
    Thompson, C.
    Hewish, M.
    Petty, R.
    Thistlethwaite, F.
    Rao, S.
    Starling, N.
    Chau, I.
    Cunningham, D.
    ESMO OPEN, 2024, 9 (07)
  • [26] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Eto, Tetsuya
    Narita, Yukiya
    Taniguchi, Hiroya
    Ura, Takashi
    Ando, Masashi
    Tajika, Masahiro
    Niwa, Yasumasa
    Yatabe, Yasushi
    Muro, Kei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 807 - 813
  • [27] Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study
    Manso, Luis
    Garcia Palomo, Andres
    Perez Carrion, Ramon
    Cassinello, Javier
    Gallegos Sancho, Isabel
    Chacon Lopez-Muniz, Ignacio
    Olier, Clara
    Fernandez-Aramburo, Antonio
    Llorca, Cristina
    Gonzalez, Xavier
    Llorente, Rosa
    Torregrosa, Dolores
    Alvarez, Inaki
    Galve, Elena
    Bueno, Coralia
    Garau, Isabel
    Garcia, Maria Jose
    Gonzalez-Santiago, Santiago
    Ballesteros, Ana Isabel
    Blanco, Esperanza
    Galan, Antonio
    Gonzalez, Sonia
    Perello, Antonia
    Cortes-Funes, Hernan
    Gravalos, Cristina
    ANTICANCER RESEARCH, 2015, 35 (12) : 6941 - 6950
  • [28] Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer
    Wang, Guocheng
    Huang, Yan
    Zhou, Liang
    Yang, Haojun
    Lin, Huang
    Zhou, Shengfang
    Tan, Zhengang
    Qian, Jun
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
  • [29] First-line chemotherapy for HER-2-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment
    Morabito, Alessandro
    Piccirillo, Maria Carmela
    Monaco, Katia
    Pacilio, Carmen
    Nuzzo, Francesco
    Chiodini, Paolo
    Gallo, Ciro
    De Matteis, Andrea
    Perrone, Francesco
    ONCOLOGIST, 2007, 12 (11): : 1288 - 1298
  • [30] Impact of Malnutrition on Prognosis in Patients with HER2-negative Metastatic Gastric Cancer
    Topcu, Atakan
    Yasin, Ayse Irem
    MEDICAL JOURNAL OF BAKIRKOY, 2022, 18 (02) : 258 - 265
12345